{
  "id": 15682500,
  "title": "Samsung Bioepis Secures 10-Year Exclusive Supply Deal in Brazil's $170 Million Rare Disease Drug Market",
  "url": "https://urgent.news/2026/10/20/samsung-bioepis-secures-10-year-exclusive-supply-deal-in-brazils-170",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-20T01:56:32.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=279173"
  },
  "original_language": "en",
  "account": "Samsung Bioepis has secured a 10-year exclusive supply deal in Brazil's $170 million rare disease drug market. The biosimilar, SB12, a copy of Soliris, will be exclusively supplied to the Brazilian government-led market starting in 2027. Samsung Bioepis will partner with Brazil's Ministry of Health and local companies Bionovis and Bahiafarma to transfer manufacturing technology. SB12, a treatment for rare diseases like PNH and aHUS, received approval from Brazil's ANVISA in December 2025. Brazil's eculizumab market was valued at around $170 million in 2025. This marks Samsung Bioepis' third PDP agreement with the Brazilian government, expanding their portfolio to include SB12.",
  "summary": "Samsung Bioepis will exclusively supply its biosimilar to Brazil's rare disease drug market, estimated at approximately $170 million, or 250 billion won, annually, for a period of 10 years.Samsung Bioepis announced on Oct. 20 that it had signed a local partnership agreement with Brazil's Ministry of",
  "key_points": [],
  "editors_take": "Securing this long-term exclusive agreement through technology transfers allows Samsung Bioepis to cement its presence within the Brazilian government-led market for high-value rare disease treatments.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}